drugset
drugset / Trial / NCT03709706

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

NCT03709706 ↗

Phase 1/2 Terminated 34 enrolled GlaxoSmithKline Merck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This trial will evaluate safety and tolerability of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with non-small cell lung cancer.

Timeline

Start
2018-12-31
Primary completion
2022-06-27
Completion
2022-11-04

Outcome

Outcome not reported

Stopped: “The study was terminated for reasons pertaining to feasibility”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lete-cel Unknown — —
Subject Pembrolizumab Monoclonal antibody — —

Indications

neoplasm